CAR T-cells: costs, comparisons, and commentary

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-Cell lymphoma in the United States

(2018) Joshua A. Roth et al.   JOURNAL OF MEDICAL ECONOMICS

CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies

(2018) Hannah M. Knochelmann et al.   Frontiers in Immunology

Trends in the global immuno-oncology landscape

(2018) Jun Tang et al.   NATURE REVIEWS DRUG DISCOVERY

Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS prodigy system

(2018) Wei Zhang et al.   Drug Design Development and Therapy

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

(2018) Susanne H. Baumeister et al.   Cancer Immunology Research

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

Immunotherapy: Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

(2017) Vinay Prasad   Nature Reviews Clinical Oncology

Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy

(2017) Lisa Rosenbaum   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12

(2015) Matthew C. Cheung et al.   JNCI-Journal of the National Cancer Institute

Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12

(2015) Matthew C. Cheung et al.   JNCI-Journal of the National Cancer Institute

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

(2014) Michael Crump et al.   JOURNAL OF CLINICAL ONCOLOGY

Driving CAR-Based T-Cell Therapy to Success

(2014) Bipulendu Jena et al.   Current Hematologic Malignancy Reports

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY